NEWSROOM | Galderma

PeDRA 2026: Nemolizumab phase II data show long-term symptom relief for children aged 2 to 11 years with moderate-to-severe atopic dermatitis

Galderma signs agreement to acquire ZO Skin Health, strengthening its physician-dispensed skincare offering

New Galderma research reveals more than half of women mistake menopause-related skin changes for signs of ageing

An unpredictable environment: navigating triggers in atopic dermatitis

Fall Clinical 2026: Galderma presents new three-year Nemluvio® data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older

For menopause-related skin changes, aesthetic treatments are gaining ground

30 years of Restylane®: reshaping the aesthetics field through science-led, patient-centric innovation

EADV 2026: Galderma’s new data show sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis

EADV 2026: Galderma’s scientific presentations and activities

EADV 2026: Galderma to unveil new data advancing understanding of skin diseases, skin longevity, and real-world patient experiences

Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies

Galderma’s Restylane® Volyme™ demonstrates high effectiveness, satisfaction and a robust safety profile in Chinese patients with temple hollowing

Galderma opens new U.S. and Latin America headquarters in Miami